Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

13.13 -0.45 (-3.31%)
Streaming Delayed Price Updated: 1:18 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
News headline image
Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year? ↗
Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge. 
Via Stocktwits
Topics ETFs
News headline image
MarketBeat’s Top 5 Rated Small-Cap Stocks ↗
Via MarketBeat
News headline image
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Reports Q3 2025 Earnings Miss Amid Accelerated Clinical Pipeline Spending ↗
MindMed reports a wider-than-expected Q3 2025 loss as it accelerates its late-stage clinical trials for MM120, targeting anxiety and depression. 
Via Chartmill
Topics Earnings
News headline image
MindMed (MNMD) Q3 2025 Earnings Call Transcript ↗
MindMed (MNMD) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Why Mind Medicine Stock Is Skyrocketing Today ↗
Via The Motley Fool
News headline image
Why Mind Medicine Stock Is Soaring Today ↗
Via The Motley Fool
News headline image
Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression ↗
Needham starts MindMed at Buy with a $28 target, citing strong Phase 3 prospects for MM120 in anxiety and depression and solid cash position. 
Via Benzinga
News headline image
The Insider Report: Panic Never Pays ↗
 
Via Benzinga
News headline image
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today ↗
Mind Medicine stock hasn't beaten the market over the last five years, but what comes next? 
Via The Motley Fool
News headline image
MindMed (MNMD) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Initial Public Offering
News headline image
MindMed Reports Strong Q2 2025 Results ↗
Via The Motley Fool
News headline image
1 Reason to Buy MindMed (MNMD) ↗
The U.S. public and the nation's politicians seem to be coming around to the idea of reforming psychedelic drug laws. Looser restrictions on research would help this company. 
Via The Motley Fool
Topics Cannabis Law Enforcement
News headline image
MindMed (MNMD) Q2 Net Loss Jumps 625% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Why Mind Medicine Gave Investors a Powerful Buzz in May ↗
Via The Motley Fool
Topics Law Enforcement
News headline image
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors ↗
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more. 
Via Benzinga
Topics Government
News headline image
Why Mind Medicine Stock Vaulted More Than 8% Higher Today ↗
Via The Motley Fool
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
News headline image
Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
The Future of Healthcare: 10 Predictions For The Next Decade
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Gap To Rally Over 69%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish ↗
The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier. 
Via Stocktwits
News headline image
Warren Buffett's State of the Market ↗
Berkshire's cash hoard is approaching "Dr. Evil" levels. 
Via The Motley Fool
News headline image
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months ↗
Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca. 
Via Stocktwits
News headline image
RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. ↗
The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks. 
Via Investor's Business Daily
News headline image
Earnings Scheduled For March 6, 2025 ↗
 
Via Benzinga
News headline image
Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish ↗
The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms. 
Via Stocktwits
News headline image
This Westlake Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.